Abstract:Background The triple negative breast cancer (TNBC) is the most malignant subtype of breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario present the mainstay in TNBC treatment, paclitaxel resistance is still a striking obstacle for cancer cure. So it is imperative to probe new therapeutic targets through illustrating the mechanisms underlying paclitaxel chemoresistance. Methods The Single cell RNA sequencing (scRNA-seq) data of TNBC cells treated with paclitaxel at different points were downloaded from the Gene Expression Omnibus (GEO) database. The Seurat R package was used to filter and integrate the scRNA-seq expression matrix. Cells were further clustered by the FindClusters function, and the gene marker of each subset was defined by FindAllMarkers function. Then, the hallmark score of each cell was calculated by AUCell R package, the biological function of the highly expressed interest genes was analyzed by the DAVID database. Subsequently, we performed pseudotime analysis to explore the change patterns of drug resistance genes and SCENIC analysis to identify the key transcription factors (TFs). Finally, the inhibitors of which were also analyzed by the CTD database. Results We finally obtained 6 cell subsets from 2798 cells, which were marked as AKR1C3+, WNT7A+, FAM72B+, RERG+, IDO1+ and HEY1+HCC1143 cell subsets, among which the AKR1C3+, IDO1+ and HEY1+ cell subsets proportions increased with increasing treatment time, and then were regarded as paclitaxel resistance subsets. Hallmark score and pseudotime analysis showed that these paclitaxel resistance subsets were associated with the inflammatory response, virus and interferon response activation. In addition, the gene regulatory networks (GRNs) indicated that 3 key TFs (STAT1, CEBPB and IRF7) played vital role in promoting resistance development, and five common inhibitors targeted these TFs as potential combination therapies of paclitaxel were identified. Conclusion In this study, we identified 3 paclitaxel resistance relevant IFs and their inhibitors, which offers essential molecular basis for paclitaxel resistance and beneficial guidance for the combination of paclitaxel in clinical TNBC therapy.

Identification of Pathways Involved in Paclitaxel Activity in Cervical Cancer.

Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer

Dna Microarray Reveals Different Pathways Responding To Paclitaxel And Docetaxel In Non-Small Cell Lung Cancer Cell Line

Identification Of Genes And Mirnas In Paclitaxel Treatment For Breast Cancer

Potential Biomarkers for Paclitaxel Sensitivity in Hypopharynx Cancer Cell.

Mir-375 is Upregulated in Acquired Paclitaxel Resistance in Cervical Cancer

Exploring the Mechanism of Paclitaxel Inhibiting T-cell Lymphoma Based on High-throughput Sequencing and Public Databases

Identification Of Cervical Cancer Proteins Associated With Treatment With Paclitaxel And Cisplatin In Patients

Single-cell Transcriptome Analyses Reveal Molecular Signals to Intrinsic and Acquired Paclitaxel Resistance in Esophageal Squamous Cancer Cells

Proteomic analysis of the proteins that are associated with the resistance to paclitaxel in human breast cancer cells.

Differential Gene Expression Profiles in Paclitaxel-Induced Cell Cycle Arrest and Apoptosis in Human Breast Cancer MCF-7 Cells.

Differential Impairment of Regulatory T Cells Rather Than Effector T Cells by Paclitaxel-Based Chemotherapy.

Microarray Expression Profile of Long Non-Coding RNAs in Paclitaxel-Resistant Human Lung Adenocarcinoma Cells.

The telomere/telomerase binding factor PinX1 regulates paclitaxel sensitivity depending on spindle assembly checkpoint in human cervical squamous cell carcinomas.

Gene And Microrna Expression Reveals Sensitivity To Paclitaxel In Laryngeal Cancer Cell Line

&Lt;p>integrative Gene Expression Profiling Reveals That Dysregulated Triple Micrornas Confer Paclitaxel Resistance in Non-Small Cell Lung Cancer Via Co-Targeting MAPT</p>

Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis

Construction of a Paclitaxel-Related Competitive Endogenous RNA Network and Identification of a Potential Regulatory Axis in Pancreatic Cancer.

Connexin 43 Modulates the Cellular Resistance to Paclitaxel via Targeting -Tubulin in Triple-Negative Breast Cancer

The Role of CYP1B1 in Paclitaxel Resistance in Breast Cancer

Drug resistance‐related gene targets and molecular mechanisms in the A2780/Taxol‐resistant epithelial ovarian cancer cell line